Is SNTS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,343 people get SNTS articles and Market Currents by email alert.

Get email alerts on SNTS »

HEADLINES:

Bull of the Day: Santarus
Zacks Investment Research • Wed, May 22
The Retire Young Portfolio: Time To Add A High-Growth Medicine Company
Jacob Steinberg • Wed, May 22
Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting

Business Wire (Fri, 7:00AM)
Santarus' CEO Presents at Bank of America/Merrill Lynch Health Care Conference (Transcript)
Thu, May 16
Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering

Business Wire (May 15, 2013)
'Superperformance' Stocks Mid-May Update
ONeil Trader • Wed, May 15 • 1 Comment
2 Biotech Companies With Strong Product Launches To Monitor
The Swiss Trader • Tue, May 14 • 3 Comments
Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder

Business Wire (May 10, 2013)
Santarus Announces Launch of a Proposed Secondary Common Stock Offering by a Selling Stockholder

Business Wire (May 9, 2013)
Review Of Depomed's First Quarter 2013 Results
Jason Napodano • Thu, May 9 • 3 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments
2 Tech Stocks And 1 Biotech With Recent Intensive Insider Selling
Markus Aarnio • Wed, May 8 • 4 Comments
Santarus CEO Discuses Q1 2013 Results - Earnings Call Transcript
Mon, May 6
Santarus Reports First Quarter 2013 Financial Results

Business Wire (May 6, 2013)
Santarus to Present at May and June Investment Conferences

Business Wire (May 3, 2013)
2 Biotechs Primed For Prosperity In 2013
MacsJV • Thu, May 2 • 17 Comments
CYCLOSET (bromocriptine mesylate) Included in American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm

Business Wire (May 2, 2013)
Santarus to Hold First Quarter 2013 Financial Results Conference Call on May 6

Business Wire (Apr 22, 2013)
Santarus and Pharming Announce Submission of RUCONEST Biologics License Application to FDA

Business Wire (Apr 17, 2013)
Santarus CEO Hosts Analyst Day (Transcript)
Thu, Apr 11 • 2 Comments

To learn more about Seeking Alpha Pro, click here.

Bull of the Day: Santarus
Zacks Investment Research • Wed, May 22
The Retire Young Portfolio: Time To Add A High-Growth Medicine Company
Jacob Steinberg • Wed, May 22
Santarus: Undervalued And Under The Radar
MacsJV • Fri, Dec 7, 2012 • 3 Comments
Santarus Plans NDA Filing On Key New Drug
Smith On Stocks • Mon, Oct 3, 2011
Santarus: Weighing A Promising Pipeline Against Patent Challenges
Smith On Stocks • Fri, Sep 16, 2011 • 2 Comments
Santarus' Late Stage Pipeline Product Budesonide MMX Is Critical To Future Growth
Smith On Stocks • Wed, Sep 14, 2011 • 3 Comments
Santarus' Q3 Loss: The Rough Path to Recovery
Michael Kudrna • Tue, Nov 9, 2010
Chart of the Week: Santarus
Michael Kudrna • Thu, Oct 21, 2010
Santarus: Building a New Company on Zegerid’s Ashes
Proactive Investor • Sun, Sep 26, 2010
Santarus: A Stock With Potential to Run
Tony Pelz • Tue, Sep 21, 2010 • 4 Comments
Santarus Beats on Higher Revenues
Zacks Investment Research • Sun, Mar 7, 2010
Santarus: Business Fundamentals Improving
Zacks Investment Research • Sun, Jun 21, 2009 • 3 Comments
Santarus Licenses OTC Heartburn Drug to Schering-Plough
Neal Shanske • Thu, Oct 19, 2006 • 2 Comments

'Superperformance' Stocks Mid-May Update
ONeil Trader • Wed, May 15 • 1 Comment
2 Biotech Companies With Strong Product Launches To Monitor
The Swiss Trader • Tue, May 14 • 3 Comments
Review Of Depomed's First Quarter 2013 Results
Jason Napodano • Thu, May 9 • 3 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments
2 Tech Stocks And 1 Biotech With Recent Intensive Insider Selling
Markus Aarnio • Wed, May 8 • 4 Comments
2 Biotechs Primed For Prosperity In 2013
MacsJV • Thu, May 2 • 17 Comments
1 Electronics Store, 1 Biotech And An Energy Company With Recent Intensive Insider Selling
Markus Aarnio • Wed, Apr 10 • 5 Comments
'Superperformance' Stocks: Potential New Stars
ONeil Trader • Tue, Apr 9 • 8 Comments
The 9 Levels Of Biotechnology And Who Should Invest: Part 2
Brian Nichols • Mon, Apr 8 • 12 Comments
5 Stocks To Watch Next Week For Gains
Brian Nichols • Sun, Apr 7 • 8 Comments
ISM Leads Market Down Bearish Path
David Brown • Mon, Apr 1
The Blitz: Are These Stocks Presenting Upside?
Brian Nichols • Sun, Mar 24 • 19 Comments
The Weekend Blitz: Finding Value, Market Behavior, & Diversification Related Plays
Brian Nichols • Mon, Mar 18 • 18 Comments
Companies That Reported 30% Sales Growth Last Week
Stock Market Joe • Wed, Mar 13 • 10 Comments
Seeking Opportunity: Creating A Plan Of Investment Action
Brian Nichols • Fri, Mar 8 • 22 Comments
FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock
PropThink • Tue, Mar 5 • 17 Comments
Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip
Ben Yoffe • Fri, Mar 1
Predicting Biotech Stock Moves Based On Consensus Picks By Legendary Fund Managers
GuruFundPicks • Tue, Feb 5 • 3 Comments
Serada Approval Presents Big Upside To Depomed
PropThink • Wed, Jan 30 • 8 Comments
Cramer's Mad Money - Is This The End For Herbalife? (1/17/13)
SA Editor Miriam Metzinger • Fri, Jan 18 • 2 Comments

Santarus' CEO Presents at Bank of America/Merrill Lynch Health Care Conference (Transcript)
Thu, May 16
Santarus CEO Discuses Q1 2013 Results - Earnings Call Transcript
Mon, May 6
Santarus CEO Hosts Analyst Day (Transcript)
Thu, Apr 11 • 2 Comments
Santarus' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Mar 4
Santarus' CEO Discusses FDA Approval of UCERIS (Budesonide) for the Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis (Transcript)
Tue, Jan 15
Santarus' CEO Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Tue, Nov 13, 2012
Santarus' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
Santarus' CEO Presents at UBS Global Life Sciences Conference (Transcript)
Wed, Sep 19, 2012 • 1 Comment
Santarus' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012
Santarus' CEO Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)
Tue, May 15, 2012
Santarus' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, May 8, 2012
Santarus' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Mon, Mar 5, 2012
Santarus' CEO Hosts Business Update Conference Call (Transcript)
Thu, Dec 22, 2011
Santarus' CEO Presents at Lazard Capital Markets 8th Annual Healthcare Conference - Event Transcript
Fri, Dec 2, 2011
Santarus' CEO Discusses Q3 2011 Results - Earnings Call Transcript
Mon, Nov 7, 2011
Santarus' CEO Discusses UBS Global Life Sciences Conference Call Transcript
Tue, Sep 20, 2011
Santarus CEO Discusses Q2 2011 Results - Earnings Call Transcript
Wed, Aug 3, 2011
Santarus CEO Discusses Q1 2011 Results - Earnings Call Transcript
Wed, May 4, 2011
Santarus Management Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Mar 3, 2011
Santarus CEO Discusses Q3 2010 Results – Earnings Call Transcript
Mon, Nov 8, 2010

Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting

Business Wire (Fri, 7:00AM)
Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering

Business Wire (May 15, 2013)
Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder

Business Wire (May 10, 2013)
Santarus Announces Launch of a Proposed Secondary Common Stock Offering by a Selling Stockholder

Business Wire (May 9, 2013)
Santarus Reports First Quarter 2013 Financial Results

Business Wire (May 6, 2013)
Santarus to Present at May and June Investment Conferences

Business Wire (May 3, 2013)
CYCLOSET (bromocriptine mesylate) Included in American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm

Business Wire (May 2, 2013)
Santarus to Hold First Quarter 2013 Financial Results Conference Call on May 6

Business Wire (Apr 22, 2013)
Santarus and Pharming Announce Submission of RUCONEST Biologics License Application to FDA

Business Wire (Apr 17, 2013)
Santarus to Host Investor and Analyst Day on April 11, 2013

Marketwire (Mar 26, 2013)
Santarus Announces Publication in Gut of Results from UCERIS (budesonide) European Pivotal Clinical Study

Business Wire (Mar 18, 2013)
Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes

Business Wire (Mar 6, 2013)
Indications: Stocks poised to top all-time closing high

at MarketWatch.com (Mar 5, 2013)
After Hours: J.C. Penney, Impax shares drop after hours

at MarketWatch.com (Mar 4, 2013)
Santarus Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Mar 4, 2013)
Santarus to Present at March Investment Conferences

Business Wire (Feb 27, 2013)
Santarus to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on March 4

Business Wire (Feb 19, 2013)
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets

Business Wire (Feb 14, 2013)
Santarus to Present at Leerink Swann Global Healthcare Conference

Business Wire (Feb 6, 2013)
Santarus and VeroScience Announce Publication of Positive Data from Pivotal CYCLOSET® (bromocriptine mesylate) Efficacy Study

Business Wire (Jan 23, 2013)

SNTS vs. ETF Alternatives

Company Description

We are a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists, endocrinologists and other physicians.

Currently Marketed and Approved Products
Our commercial... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 9:10 AM Premarket gainers: PGNX +26%. UNIS +21%. UBNT +19%. SQNM +11%. MCP +11%. XIN +7%. NBG +6%. NTE +5%. MT +5%.
Losers: PTIE -48%. IFMI -36%. AFFY -18%. SNTS -7%. OPTR -7%. DDD -6%. MDRX -6%. LFVN -5%. Comment! [On the Move]
Thursday, May 9, 6:16 PM Santarus (SNTS) announces a secondary offering of shares of its common stock. All shares will be offered by Cosmo Technologies. SNTS isn't selling any shares or receiving any proceeds from the offering. No details as to the actual size or terms of the offering were disclosed. Jefferies LLC is acting as the sole book-running manager. Shares -6% AH. Comment! [Healthcare, On the Move]
Thursday, May 9, 5:54 PM After-hours top gainers, as of 5:30 p.m.: UBNT +10%. UNIS +10%. MCP +7%. WIFI +7%. DAR +6%.
After-hours top losers: ONTY -10%. AL -8%. AIRM -7%. SNTS -6%. TSEM -6%. Comment! [On the Move]
Tuesday, May 7, 9:13 AM Premarket gainers: SNTS +11%. ALU +11%. CVLT +8%. HIMX +7%. NSM +7%. FOSL +6%. DTV +6%.
Losers: RKUS -24%. ARUN -17%. AKRX -7%. PAL -6%. 1 Comment [On the Move]
Monday, May 6, 5:49 PM After-hours top gainers, as of 5:30 p.m.: SNTS +10%. MELI +9%. NLS +9%. ININ +6%. ROIC +6%.
After-hours top losers: RKUS -16%. NSPR -4%. AZPN -3%. HOLX -3%. AXL -3%. Comment! [On the Move]
Monday, May 6, 4:56 PM More on Santarus (SNTS): Q1 blows out bottom line estimates, doubling what the Street was looking for on higher royalty and licensing payments, plus significant growth in net sales of a number of its key drugs. Total revenues grew 73% Y/Y, boosted by the commercial launch of its colitis drug Ulceris and a big jump in prescriptions written: Glumetza new prescriptions +21%, total prescriptions +18%; Clyoset new prescriptions +21%, total prescriptions +44%. Additionally, sales of Zegerid since its re-launch in February after regaining exclusivity nearly tripled to $24.5M. Shares +10.5% AH. 1 Comment [Healthcare, On the Move, Earnings]
Monday, May 6, 4:39 PM Shares of Santarus (SNTS) resume trading, currently +8.5%. Comment! [Healthcare, On the Move]
Monday, May 6, 4:14 PM More on Santarus (SNTS) earnings: Sees FY13 EPS of $1.03 - $1.15, versus prior guidance of $0.92 - 1.00 and the Street consensus of $0.76. Also sees FY13 revenue of $330M -$340M, versus prior guidance of $320M - 325M and the consensus of $339.3M. Shares currently halted. Comment! [Healthcare, Earnings]
Monday, May 6, 4:11 PM Santarus (SNTS): Q1 EPS of $0.32 beats by $0.18. Revenue of $79.44M (+73% Y/Y) beats by $4.7M. (PR). Shares are currently halted. Comment! [Healthcare, Earnings, On the Move, Breaking News]
Monday, May 6, 12:10 AM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Sunday, May 5, 5:35 PM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Wednesday, April 17, 7:12 AM Santarus (SNTS) and Pharming (PHGUF.PK) say they have filed a Biologics License Application with the FDA for the angioedema treatment RUCONEST. The drug was developed by Pharming and is licensed to Santarus for marketing in North America. If the application is accepted for review, SNTS will owe Pharming a $5M milestone payment. Comment! [Healthcare]
Thursday, April 4, 5:47 PM After-hours top gainers, as of 5:15 p.m.: WDFC +6%. MAKO +5%. CAJ +3%. SNTS +3%. OIBRC +2%.
After-hours top losers: NGD -7%. HMY -6%. CDE -6%. JNPR -5%. IAG -5%. Comment! [On the Move]
Tuesday, March 5, 12:55 PM Midday top 10 gainers: ACUR +59%. HIMX +37%. MTG +25%. CREE +15%. APP +15%. ZOLT +15%. ASNA +14%. SNTS +14%. PKOH +14%. DYAX +13%.
Midday top 10 losers: IPXL -25%. RNIN -23%. DRWI -19%. REGI -17%. TELOZ -17%. SHIP -14%. CSUN -10%. SDT -10%. JCP -10%. PSTR -9%. Comment! [On the Move]
Tuesday, March 5, 11:18 AM Santarus (SNTS +13.2%) continues to rally this morning on the back of a blowout Q4. Net earnings nearly tripled as the specialty-biopharmaceutical company reported double-digit revenue growth and gave upbeat earnings guidance for FY13, now expecting to earn $320M to $325M in revenues and net income of $50M to $54M. 2 Comments [Healthcare, Earnings, On the Move]
Tuesday, March 5, 9:10 AM Premarket gainers: HIMX +21%. ASNA +13%. ACRX +12%. MTG +11%. SNTS +9%. CREE +6%.
Losers: IPXL -21%. RNIN -16%. Comment! [On the Move]

ONeil Trader
Superperformance stocks - mid-May update http://goo.gl/QMrRv $TSLA $DDD $SNTS $PRLB $SPY
May 16, 6:05 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ONeil Trader
$SNTS nice recovery after the insider selling announcement
May 10, 2:55 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ONeil Trader
Superperformance stocks doing very well since the article http://goo.gl/RZ1EZ $TSLA 90% $DDD +35% $PRLB +25% $SNTS +20%
May 10, 10:27 AM
Reply (2)

• !Report Abuse
View all 2 replies
Skull & Bones: EVERYTHING performs during the "Euphoria" Phase of the Market Cycle.
May 10, 10:33 AM
• !Report Abuse
ONeil Trader: Not everything. Look at gold and silver stocks just as an example, and many more.
May 10, 10:50 AM
• !Report Abuse
Add a reply...

140 characters

ONeil Trader
$SNTS bought tdy at the lows of the yday's gap, low risk entry with a tight stop $$
May 8, 3:41 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ONeil Trader
Low volume pullback in $SNTS, looking good... potential superperformance stock http://goo.gl/RZ1EZ along with $DDD $PRLB $TSLA
May 8, 3:19 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Santarus ($SNTS) is riding the wave from its recently approved mild-to-moderate ulcerative colitis drug. http://yhoo.it/16WutEj
May 8, 2:03 AM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: But up 200%?
May 8, 2:03 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
MercadoLibre ($MELI), Santarus ($SNTS), Gentherm ($THRM), Nationstar Mortgage ($NSM), Oaktree Capital ($OAK) rose Tuesday on unusual vol.
May 8, 1:48 AM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: $MELI rose on unusual volume on Friday. Mentioned it Monday morning. Nice 17% gain today. Still a longterm buy.
May 8, 1:51 AM
• !Report Abuse
Add a reply...

140 characters

ONeil Trader
Nice day for $SNTS after an earnings beat yday... one of my potential superperformers http://goo.gl/RZ1EZ
May 7, 10:23 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ONeil Trader
The new superperformance stocks http://goo.gl/RZ1EZ they are up between 15% and 45% in one month $DDD $TSLA $SNTS $PRLB $STUDY
May 7, 9:56 AM
Reply (2)

• !Report Abuse
View all 2 replies
J. A. Saglimbeni: Long $PRLB, as you know O-Trader...and $DDD is acting well as of late.
May 7, 10:15 AM
• !Report Abuse
ONeil Trader: $DDD not today, but looking good, $PRLB behaving rather nicely after a sharp move down few weeks ago
May 7, 10:25 AM
• !Report Abuse
Add a reply...

140 characters

ONeil Trader
All potential superperformers doing well since the article was published http://goo.gl/RZ1EZ $DDD $PRLB $SNTS $TSLA
May 6, 4:33 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

ONeil Trader
Superperformance stocks doing very well since the article http://goo.gl/RZ1EZ $TSLA 90% $DDD +35% $PRLB +25% $SNTS +20%
May 10, 10:27 AM
Reply (2)

• !Report Abuse
View all 2 replies
Skull & Bones: EVERYTHING performs during the "Euphoria" Phase of the Market Cycle.
May 10, 10:33 AM
• !Report Abuse
ONeil Trader: Not everything. Look at gold and silver stocks just as an example, and many more.
May 10, 10:50 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Santarus ($SNTS) is riding the wave from its recently approved mild-to-moderate ulcerative colitis drug. http://yhoo.it/16WutEj
May 8, 2:03 AM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: But up 200%?
May 8, 2:03 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
MercadoLibre ($MELI), Santarus ($SNTS), Gentherm ($THRM), Nationstar Mortgage ($NSM), Oaktree Capital ($OAK) rose Tuesday on unusual vol.
May 8, 1:48 AM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: $MELI rose on unusual volume on Friday. Mentioned it Monday morning. Nice 17% gain today. Still a longterm buy.
May 8, 1:51 AM
• !Report Abuse
Add a reply...

140 characters

ONeil Trader
The new superperformance stocks http://goo.gl/RZ1EZ they are up between 15% and 45% in one month $DDD $TSLA $SNTS $PRLB $STUDY
May 7, 9:56 AM
Reply (2)

• !Report Abuse
View all 2 replies
J. A. Saglimbeni: Long $PRLB, as you know O-Trader...and $DDD is acting well as of late.
May 7, 10:15 AM
• !Report Abuse
ONeil Trader: $DDD not today, but looking good, $PRLB behaving rather nicely after a sharp move down few weeks ago
May 7, 10:25 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Pinnacle Financial ($PNFP), Tenet Healthcare ($THC), Alaska Air ($ALK), Sherwin-Williams ($SHW), & Santarus ($SNTS) rose Tues on unusual vol
Apr 17, 12:37 AM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: $SNTS has shown up for 2 days in a row (excluding Monday where everything fell). Institutional buying?
Apr 17, 12:45 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Bloomin' Brands ($BLMN), Telekom Indonesia ($TLK), Alkermes ($ALKS), Fortune Brands ($FBHS), & Santarus ($SNTS) rose Friday on unusual vol.
Apr 14, 11:22 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: Buy $TLK and $FBHS.
Apr 14, 11:25 PM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
Your Dose of Stocks That Only Go Up | $V $EXPE $RYL $AMT $AOS $CONN $FISV HD $LPX $PPG $SNTS $STC $TYL http://bit.ly/RzGOIi
12/4/12
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: And $EXR.
12/4/12
• !Report Abuse
Ryan Mallory: yes - agree!
12/4/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
And another one, $SNTS I suggested in the following article was a good catalyst potential trade @ http://seekingalpha.com/a/i5k3
9/13/12
Reply (1)

• !Report Abuse
View all 1 replies
koksiang_darren: any upcoming news on Antares?
9/14/12
• !Report Abuse
Add a reply...

140 characters

Alpha1Omega1
Three stocks that will double in the next 18 - 24 months: SNTS, DDD and SSYS.
7/16/12
Reply (1)

• !Report Abuse
View all 1 replies
tashe: SSYS clsd @ 51.35 up 3.81 (8.01 %) abv avg vol DDD clsd @ 34.25 up 1.23 (3.73 %) abv avg vol SNTS clsd @ 7.51 up 0.11 (1.49 %) blow av vol
7/16/12
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Potential Trades w/Charts: Markets Refuse To Pullback #KSMT $SPY $IWM $QQQ $DJIA $TBT $DEJ $NANO $PRFT $SNTS http://bit.ly/wq3tYM
1/9/12
Reply (5)

• !Report Abuse
View all 5 replies
Michael Kudrna: no prob...that doesn't mean I dont like all four, I do, just haven't had right buying time/room to get all four in portfolio
1/10/12
• !Report Abuse
Hillbilly Stock Star: Gotcha!
1/10/12
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Weekly Homework: Here Comes Santa Claus (w/ Econ Calendar & StockRadar) $FTK $SNTS $MHR $LNG $CBOU $TBT $SPY $GLUU http://bit.ly/sJkDi6
12/26/11
Reply (6)

• !Report Abuse
View all 6 replies
JCH57: I may re-buy on a dip, then. My feel is that all-time historical lows in bond yields sounds like a monster bubble is about to pop.
12/26/11
• !Report Abuse
Michael Kudrna: Agreed, it's just a matter of time, but I'd rather get in when it first pops than try to predict when it will pop
12/26/11
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
$SWHC and $SNTS, both from my Sunday night stock radar are acting well, no positions yet $$
12/22/11
Reply (3)

• !Report Abuse
View all 3 replies
Michael Kudrna: depends your timeframe...but Im waiting on a pullback to see where it settles before I buy, but it never pulls back
12/22/11
• !Report Abuse
Brandon Gibbs: lol exactly
12/22/11
• !Report Abuse
Add a reply...

140 characters

SNTS Santarus, Inc.

SNTS

Santarus, Inc.